Sangamo Therapeutics Stock Analysis
SGMO Stock | USD 1.96 0.01 0.51% |
Sangamo Therapeutics is undervalued with Real Value of 3.07 and Target Price of 6.58. The main objective of Sangamo Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Sangamo Therapeutics is worth, separate from its market price. There are two main types of Sangamo Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Sangamo Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Sangamo Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Sangamo Stock trading window is adjusted to America/New York timezone.
Sangamo |
Sangamo Stock Analysis Notes
About 39.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.24. Sangamo Therapeutics had not issued any dividends in recent years. Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California. Sangamo Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about Sangamo Therapeutics contact ChB MB at 510 970 6000 or learn more at https://www.sangamo.com.Sangamo Therapeutics Quarterly Total Revenue |
|
Sangamo Therapeutics Investment Alerts
Sangamo Therapeutics is way too risky over 90 days horizon | |
Sangamo Therapeutics may become a speculative penny stock | |
Sangamo Therapeutics appears to be risky and price may revert if volatility continues | |
Sangamo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M). | |
Sangamo Therapeutics currently holds about 315.72 M in cash with (224.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Sangamo Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from simplywall.st: Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. Forecasts |
Sangamo Therapeutics Upcoming and Recent Events
Earnings reports are used by Sangamo Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
28th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Sangamo Largest EPS Surprises
Earnings surprises can significantly impact Sangamo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2010-07-28 | 2010-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2003-04-29 | 2003-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2002-10-30 | 2002-09-30 | -0.09 | -0.1 | -0.01 | 11 |
Sangamo Stock Institutional Investors
Shares | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Two Sigma Advisers, Llc | 2024-06-30 | 820.4 K | Hightower Advisors, Llc | 2024-06-30 | 792.3 K | Y-intercept (hong Kong) Ltd | 2024-06-30 | 744.1 K | Susquehanna International Group, Llp | 2024-06-30 | 670.1 K | Jane Street Group Llc | 2024-06-30 | 600.6 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 576.2 K | Fmr Inc | 2024-09-30 | 544 K | Two Sigma Investments Llc | 2024-06-30 | 543.2 K | Wasatch Advisors Lp | 2024-06-30 | 20.1 M | Armistice Capital, Llc | 2024-06-30 | 14.1 M |
Sangamo Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 563.24 M.Sangamo Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.56) | (1.48) | |
Return On Capital Employed | (2.33) | (2.21) | |
Return On Assets | (1.56) | (1.48) | |
Return On Equity | (3.11) | (2.96) |
Management Efficiency
Sangamo Therapeutics has return on total asset (ROA) of (0.5829) % which means that it has lost $0.5829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9405) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -2.21. At this time, Sangamo Therapeutics' Total Assets are very stable compared to the past year. As of the 21st of November 2024, Non Currrent Assets Other is likely to grow to about 19 M, while Other Assets are likely to drop 0.95.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.48 | 0.45 | |
Tangible Book Value Per Share | 0.48 | 0.45 | |
Enterprise Value Over EBITDA | (1.00) | (1.05) | |
Price Book Value Ratio | 1.14 | 1.09 | |
Enterprise Value Multiple | (1.00) | (1.05) | |
Price Fair Value | 1.14 | 1.09 | |
Enterprise Value | 78.9 M | 75 M |
Sangamo Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin (94.13) | Beta 1.098 | Return On Assets (0.58) | Return On Equity (1.94) |
Technical Drivers
As of the 21st of November, Sangamo Therapeutics has the Risk Adjusted Performance of 0.1455, coefficient of variation of 552.79, and Semi Deviation of 4.54. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sangamo Therapeutics, as well as the relationship between them.Sangamo Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Sangamo Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Sangamo Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Sangamo Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sangamo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sangamo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sangamo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sangamo Therapeutics Outstanding Bonds
Sangamo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sangamo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sangamo bonds can be classified according to their maturity, which is the date when Sangamo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Sangamo Therapeutics Predictive Daily Indicators
Sangamo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sangamo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sangamo Therapeutics Forecast Models
Sangamo Therapeutics' time-series forecasting models are one of many Sangamo Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sangamo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Sangamo Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Sangamo Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sangamo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Sangamo Therapeutics. By using and applying Sangamo Stock analysis, traders can create a robust methodology for identifying Sangamo entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (1.49) | (1.57) | |
Operating Profit Margin | (1.55) | (1.63) | |
Net Loss | (1.46) | (1.54) | |
Gross Profit Margin | (0.26) | (0.24) |
Current Sangamo Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sangamo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sangamo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.58 | Buy | 8 | Odds |
Most Sangamo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Sangamo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Sangamo Therapeutics, talking to its executives and customers, or listening to Sangamo conference calls.
Sangamo Stock Analysis Indicators
Sangamo Therapeutics stock analysis indicators help investors evaluate how Sangamo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sangamo Therapeutics shares will generate the highest return on investment. By understating and applying Sangamo Therapeutics stock analysis, traders can identify Sangamo Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 101.9 M | |
Common Stock Shares Outstanding | 174.4 M | |
Total Stockholder Equity | 82.9 M | |
Tax Provision | -4.5 M | |
Property Plant And Equipment Net | 52.9 M | |
Cash And Short Term Investments | 81 M | |
Cash | 45.2 M | |
Accounts Payable | 15.3 M | |
Net Debt | -7.1 M | |
50 Day M A | 1.2712 | |
Total Current Liabilities | 47.7 M | |
Other Operating Expenses | 450.2 M | |
Non Current Assets Total | 71 M | |
Non Currrent Assets Other | 18.1 M | |
Stock Based Compensation | 27.4 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.